#233 
 
Guidance for Industry 
 
Veterinary Feed Directive 
Common Format 
Questions and Answers 
 
 
Submit comments on this guidance at any time.  Submit electronic comments to 
http://www.regulations.gov.  Submit written comments to the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 
20852.  All comments should be identified with the docket number FDA-2010-N-0155. 
 
For further information regarding this document, contact AskCVM@fda.hhs.gov. 
 
Additional copies of this guidance document may be requested from the Policy and Regulations 
Staff (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish 
Place, Rockville, MD 20855, and may be viewed on the Internet at either 
http://www.fda.gov/AnimalVeterinary/default.htm or http://www.regulations.gov. 
 
 
 
 
U.S. Department of Health and Human Services 
Food and Drug Administration 
Center for Veterinary Medicine 
September 2016 
    Contains Nonbinding Recommendations 
Table of Contents 
 
 
I. INTRODUCTION ....................................................................................................................... 3 
II. VETERINARY FEED DIRECTIVE ......................................................................................... 4 
A.  Sponsor Submission of a Veterinary Feed Directive ....................................................... 4 
1.  What responsibilities does a sponsor have for creating and submitting a VFD to 
CVM? ................................................................................................................................4 
2.  Can a sponsor submit a VFD that does not include the VFD drug-specific 
information to meet the requirements of  514.1(b)(9)? ...................................................4 
3.  What VFD drug-specific information should be pre-populated on the VFD at the 
time a sponsor submits a VFD to CVM as part of the new animal drug 
application? .......................................................................................................................4 
4.  What information should not be pre-populated on the VFD at the time a sponsor 
submits a VFD to CVM as part of the new animal drug application? ..............................5 
5.  Is a sponsor allowed to further customize the VFD after CVM has approved the 
VFD? .................................................................................................................................6 
6.  Can a sponsor pre-populate information into the special instructions area of the 
VFD? .................................................................................................................................7 
7.  Can the sponsor include other information on the VFD? ..................................................7 
8.  Should the VFD have the proprietary name (trade name) or established name of 
the VFD drug(s)? ..............................................................................................................8 
B.  Veterinary Feed Directive Information and Recommended Common Format ............... 8 
1.  What information is required to be on the VFD and what information is 
discretionary? ( 558.6(b)(3) and (4)) ............................................................................8 
2.  In what order should the information be included on the VFD? .......................................9 
3.  Do all three affirmation of intent statements need to be included for a VFD drug 
with no approved, conditionally approved, or indexed combination with other 
animal drug(s)? ...............................................................................................................10 
4.  How does the recommended common format apply to an electronic VFD? ..................11 
5.  The examples in the appendices do not include space for additional information a 
sponsor may want to include, such as a logo.  Can this information be included on 
the VFD? .........................................................................................................................11 
Appendix A:  Blank VFD in the recommended common format ................................................. 12 
Appendix B:  Examples of VFDs in the recommended common format pre-populated by the 
sponsor for submission to CVM ................................................................................................... 13 
Appendix C:  Examples of pre-populated VFDs in the recommended common format that have 
subsequently been completed by the issuing veterinarian ............................................................ 15 
   
2  Contains Nonbinding Recommendations 
Guidance for Industry 
 
Veterinary Feed Directive Common Format Questions and Answers 
 
This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on 
this topic.  It does not establish any rights for any person and is not binding on FDA or the public.  You 
can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.  
To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the 
title page. 
 
I. INTRODUCTION 
 
On December 12, 2013, the Food and Drug Administration (FDA) published a proposed rule to 
revise the veterinary feed directive (VFD) regulations in Title 21 of the Code of Federal 
Regulations section 558.6 (21 CFR 558.6), and introduce clarifying changes to the related 
definitions in 21 CFR 558.3.  In June 2015 FDA published the final rule.  Concurrently with the 
final rule, FDA published draft Guidance for Industry (GFI) #120 entitled Veterinary Feed 
Directive Regulation Questions and Answers to provide guidance on the final rule.  FDA 
announced the availability of final GFI #120 (a small entity compliance guide) in September 
2015. 
 
A few of the comments in response to the proposed rule requested that FDA require a uniform 
veterinary feed directive (VFD) form.  We declined this request because we thought that 
requiring a specific VFD form would be too prescriptive.  However, we acknowledge that a 
common VFD format would help veterinarians, their clients (i.e., animal producers), and 
distributors (including feed mills) quickly identify relevant information on the VFD.  Therefore, 
we are issuing this guidance to recommend a common VFD format.  In this guidance, when we 
use the term VFD, we are referring to the form used to convey the VFD order. 
 
FDA regulations at 21 CFR 514.1(b)(9) require that an animal drug sponsor who is seeking 
approval of a drug for use in or on feed as a VFD drug must submit copies of a VFD for review 
by FDAs Center for Veterinary Medicine (CVM) in a form that accounts for the information 
described under  558.6(b)(3) and 558.6(b)(4) as part of the application process.  This 
guidance addresses the requirement for sponsor submission of a VFD found in  514.1(b)(9), and 
recommends a common format for the information to be included on the VFD.  Once the 
sponsors drug is approved, the VFD form provided by the sponsor will be made available for 
use by veterinarians when authorizing their client to obtain and use medicated feed containing 
the VFD drug.  (Please note that a veterinarian is not required to use the sponsors form and may 
instead create his or her own VFD form.)  This document also provides guidance concerning the 
elements that must be included on the VFD as required by  558.6(b)(3) and the elements that 
may be included on the VFD as described in  558.6(b)(4).  Finally, this guidance provides 
examples that illustrate how a common VFD format might appear and how some information 
may be pre-populated on the VFD by the sponsor and subsequently completed with all of the 
3  Contains Nonbinding Recommendations 
remaining relevant information filled out by the issuing veterinarian.1  This guidance only covers 
the contents and format of the VFD.  Guidance for Industry #120, Veterinary Feed Directive 
Regulation Questions and Answers, contains more comprehensive information about the VFD 
process, including information about the requirements for authorizing, manufacturing, 
distributing, and using VFD drugs in animal feed. 
 
In general, FDA guidance documents do not establish legally enforceable responsibilities.  
Instead, guidances describe the Agencys current thinking on a topic and should be viewed only 
as recommendations, unless specific regulatory or statutory requirements are cited.  The use of 
the word should in Agency guidance means that something is suggested or recommended, but 
not required. 
 
II. VETERINARY FEED DIRECTIVE 
 
A.  Sponsor Submission of a Veterinary Feed Directive 
 
1.  What responsibilities does a sponsor have for creating and submitting a VFD to 
CVM? 
 
As part of the application process for approval of a new animal drug for use in or on animal feed 
as a VFD drug, the drug sponsor is required to submit for FDA review three copies of a VFD in a 
format that accounts for the information described under  558.6(b)(3) and 558.6(b)(4). 
( 514.1(b)(9)).  Once the sponsors drug is approved, veterinarians have the option2 to use the 
sponsors VFD form when authorizing his or her client to obtain and use medicated feed 
containing the VFD drug. 
 
2.  Can a sponsor submit a VFD that does not include the VFD drug-specific 
information to meet the requirements of  514.1(b)(9)? 
 
No.  A sponsor's VFD must account for the VFD drug-specific information described in  
558.6(b)(3) and (b)(4) to meet the requirements of  514.1(b)(9). 
 
3.  What VFD drug-specific information should be pre-populated on the VFD at the 
time a sponsor submits a VFD to CVM as part of the new animal drug 
application? 
 
A VFD pre-populated by the sponsor likely will reduce the risk of a veterinarian making an error 
or leaving out required information when filling in the form.  Sponsors should pre-populate the 
VFD with the information that is required to be included on the VFD by the VFD regulation 
found at  558.6, and also with other information that does not require the veterinarian's 
discretion when authorizing the VFD.  In addition, the pre-populated VFD should contain areas 
                                                 
1 We encourage sponsors with currently approved VFDs and veterinarians generating their own VFDs to also follow 
the VFD common format outlined in this guidance. 
2 Alternatively, veterinarians may create their own VFD.  When doing so, they may choose to follow the common 
format outlined in this guidance. 
4  Contains Nonbinding Recommendations 
designated on the form to account for the rest of the information that can only be provided by the 
veterinarian at the time the VFD is issued. 
 
We recommend that, at a minimum, sponsors pre-populate the following information on the 
VFD submitted to CVM as part of the new animal drug application to reflect the conditions of 
approval, conditional approval, or index listing: (1) drug name(s); (2) drug level and duration of 
use (exact level or ranges as approved); (3) indication(s)3; (4) species and production class(es); 
(5) withdrawal time(s); (6) near the space where the veterinarian includes the expiration date, the 
maximum expiration date specified in the approval, conditional approval, or index listing, or 6 
months if a date is not otherwise specified; (7) the maximum number of reorders (refills) 
permitted by the drug approval, conditional approval, or index listing or, if none are permitted, 
the statement, Refills of this VFD are not permitted.; (8) any special instructions specified on 
the approved labeling as necessary for use of the drug; (9) the statement, Use of feed containing 
this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling 
(extralabel use) is not permitted.; and (10) cautionary statements (including warnings) necessary 
for use of the drug in conformance with the approval, conditional approval, or index listing.  
Special instructions, cautionary statements, and warnings found on the approved representative 
Type C medicated feed (Blue Bird) labeling should appear on the VFD. 
 
4.  What information should not be pre-populated on the VFD at the time a sponsor 
submits a VFD to CVM as part of the new animal drug application? 
 
There is some information that a sponsor would generally be unable to pre-populate on the VFD 
because that type of information can only be filled in by the veterinarian once he or she has 
engaged with a particular client.  This includes: (1) the client name, business or home address, 
and telephone number; (2) veterinarian name, address, and telephone number; (2) the premises at 
which the animals specified on the VFD are located; (3) the date of VFD issuance; (4) the VFD 
expiration date (a date not to exceed the date as specified in the approval, conditional approval, 
or index listing, or if not specified, not to exceed 6 months); (5) the approximate number of 
animals to be fed the VFD feed by the expiration date of the VFD; (6) the veterinarians special 
instructions; (7) the number of reorders (refills) authorized by the veterinarian (not to exceed the 
number permitted by the drug approval, conditional approval, or index listing, if any); (8) more 
specific identification of the animals to be treated as allowed by  558.6(b)(4); (9) the 
veterinarians affirmation of intent for combination VFD drugs as described in  558.6(b)(6); and 
(10) the veterinarian's signature. 
 
Several pieces of information required on the VFD result from the veterinarian's professional 
judgment and discretion but, based on the conditions and indications of use of the drug as set 
forth in the relevant approval, conditional approval, or index listing, the veterinarian may have 
limited options from which to choose.  At a minimum, the VFD submitted to CVM by the 
                                                 
3 The statements that are required to be on VFDs for approved, conditionally approved, and index listed drugs are 
different; thus, the sponsor should create a separate pre-populated VFD containing the relevant information for each 
category of legally marketed drugs (i.e., approved, conditionally approved, or index listed).  Should the VFD reflect 
multiple indications in the same legal marketing category, we recommend that checkboxes be placed in front of each 
listed indication (with its associated species and production class, dose and duration of use, and withdrawal time) for 
the veterinarian to select which indication he or she is authorizing under the VFD. 
5  Contains Nonbinding Recommendations 
sponsor should have identified space available for this information.  The sponsor may pre-
populate all of the optional information available to the veterinarian under the approval, 
conditional approval, or index listing by using formatting such as checkboxes or blanks for the 
veterinarian to indicate his or her decision.  For example, if a VFD drug is a component of an 
approved, conditionally approved, or indexed combination VFD drug, the sponsor should include 
all three affirmation of intent statements on the VFD for the veterinarian to choose from.  If a 
VFD drug is not a component of an approved, conditionally approved, or indexed combination 
VFD drug, the sponsor should include only the statement, This VFD only authorizes the use of 
the VFD drug(s) cited in this order and is not intended to authorize the use of such drug(s) in 
combination with any other animal drugs. 
 
Furthermore, when the veterinarian's options are limited by the approval, conditional approval, 
or index listing, the sponsor should provide blank space with information in a parenthetical that 
indicates the approved options available to the veterinarian.  For example, the expiration date 
should have a blank line with a parenthetical that indicates the maximum expiration date allowed 
by the approval, conditional approval, or index listing (e.g., Exp. Date: ____ (not to exceed 21 
days)).  Another example is when the approval, conditional approval, or index listing allows the 
veterinarian to select a drug level from within a range.  In that case, the sponsor should include 
space for the veterinarian to indicate the specific authorized drug level, as well as pre-populated 
parenthetical information about the range allowed by the approval, conditional approval, or index 
listing (e.g., Drug level: _____ g/ton (20-40 g/ton). If the drug level in the approval, conditional 
approval, or index listing is specified in units other than g/ton (e.g., mg/head/day or mg/unit 
body weight/day), then the sponsor should include space for the veterinarian to indicate the 
specific drug level in the feed in g/ton that corresponds with the dose level. 
 
5.  Is a sponsor allowed to further customize the VFD after CVM has approved the 
VFD? 
 
Some drugs may be approved for more than one use (e.g., multiple indications).  Sponsors of 
such drugs may wish to create VFDs that contain information relevant to more than one 
approved use of the drug in order to make them more user friendly for veterinarians.4  CVM will 
accept further revisions to the VFD after approval so long as the sponsors customization: (1) 
conforms with the approved or conditionally approved application, or index listing; (2) includes 
all of the pre-populated information and spaces for the veterinarian-specified information that 
was included in the VFD(s) submitted to and approved by CVM; (3) includes all of the options 
available to a veterinarian consistent with the approval, conditional approval, or index listing; 
and (4) clearly organizes these options (for example, it should be clear which drug level, 
duration, withdrawal period, and cautionary statements, etc., correspond to a particular species, 
class, and/or indication).  We think that this customization may, in some instances, reduce the 
possibility that veterinarians may accidentally omit required information or include information 
not allowed by the approval, conditional approval, or index listing. 
 
                                                 
4The statements that are required to be on VFDs for approved, conditionally approved, and index listed drugs are 
different; thus, the sponsor should create a separate pre-populated VFD containing the relevant information for each 
category of legally marketed drugs (i.e., approved, conditionally approved, or index listed). 
6  Contains Nonbinding Recommendations 
6.  Can a sponsor pre-populate information into the special instructions area of the 
VFD? 
 
Generally, the special instructions area should be reserved for special instructions that appear on 
the approved representative Type C medicated feed (Blue Bird) labeling.  A sponsor should pre-
populate information in this area only if this information is always necessary for use of the VFD 
drug in conformance with the approval, conditional approval, or index listing, and is not already 
included elsewhere on the VFD as part of the information required by  558.6(b)(3) or permitted 
by  558.6(b)(4). 
 
The special instructions area also provides space for the veterinarian to communicate information 
necessary for the appropriate treatment of the animals and/or the use of the VFD feed, relevant to 
the specific clients and patients for whom they are authorizing the VFD.  Examples of this type 
of information include: 
 
  Specific treatment instructions the veterinarian wants the client to follow that are 
allowable under the approval, conditional approval, or index listing, but may be 
impractical to include elsewhere on the VFD.  For example, if a VFD drug can be used 
within a certain drug level range and the veterinarian would like the client to use a higher 
drug concentration within that range for a certain part of the treatment duration and a 
lower drug concentration within that range for another part of the treatment duration, the 
special instructions area could be used for that purpose. 
  Specific response monitoring instructions the veterinarian wants the client to follow.  For 
example, the veterinarian may want the client to monitor the animals daily and call if the 
symptoms do not improve after a certain number of days. 
  Specific husbandry practices the veterinarian wants the client to follow to achieve 
maximum treatment results (e.g., weather or housing considerations); 
  A reminder to the client to follow all labeling instructions.  The veterinarian may want to 
specifically remind the client that if they choose to use the VFD drug in a combination 
feed the veterinarian has authorized with the affirmation statements, that labeling 
information such as withdrawal times and caution statements may differ and the client 
should comply with the information on the labeling for the combination feed. 
 
7.  Can the sponsor include other information on the VFD? 
 
Because non-required information that is placed on the VFD can create confusion and make it 
more difficult to locate required information, we recommend limiting the information on the 
VFD to the required and discretionary information listed in  558.6(b)(3) and (b)(4).  We also 
recommend that any non-required information the veterinarian or sponsor may choose to include 
on a VFD be in a place and manner that does not interfere with the required and discretionary 
information listed in  558.6(b). 
 
   
7  Contains Nonbinding Recommendations 
8.  Should the VFD have the proprietary name (trade name) or established name of 
the VFD drug(s)? 
 
The name of the VFD drug is required to be included on the VFD. ( 558.6(b)(3)(vi)).  The 
veterinarian may choose to write either the established name (e.g., florfenicol, tilmicosin) or the 
proprietary name (trade name) of a specific VFD drug. 
 
If the VFD lists a VFD drug by the proprietary name (trade name), the veterinarian may choose 
to specify that a substitution by the feed manufacturer is not allowed.  For a sponsor-generated 
VFD that has the drug name pre-populated with the trade name, the sponsor may include a 
checkbox with the statement [ ] Drug product substitution is not allowed if checked.  
Nevertheless, if the sponsor does not include a checkbox on the VFD, the veterinarian may write 
on the VFD that substitution is not allowed as part of their authorization. 
 
If the VFD lists a drug by the proprietary name but the veterinarian does not specify that a 
substitution is not allowed, the feed manufacturer may use either the approved pioneer or any 
approved generic VFD drug to manufacture the VFD feed provided that the approval for the drug 
being used is consistent with the information on the VFD order (e.g., approved for that 
indication, in that species and production class, and at the drug level specified on the order).  
However, the feed manufacturer may not substitute a generic VFD drug for a pioneer VFD drug 
in a combination VFD feed if the generic VFD drug is not a component of an approved 
combination VFD drug (21 U.S.C. 360b(a)). 
  
If the VFD lists a VFD drug by an established name, the feed manufacturer may use the 
approved pioneer or any approved generic VFD drug to manufacture the VFD feed provided that 
the approval for the drug being used is consistent with the information on the VFD order (e.g., 
approved for that indication, in that species and production class, and at the drug level specified 
on the order).  However, the feed manufacturer may not use a pioneer VFD drug or a generic 
VFD drug in a combination VFD feed if the pioneer or generic VFD drug is not a component of 
an approved combination VFD drug (21 U.S.C. 360b(a)). 
 
B.  Veterinary Feed Directive Information and Recommended Common Format 
 
1.  What information is required to be on the VFD and what information is 
discretionary? ( 558.6(b)(3) and (4)) 
 
The regulation at  558.6(b)(3) requires that the following information be fully and accurately 
included on the VFD: 
 
  the veterinarians name, address, and telephone number; 
  the clients name, business or home address, and telephone number; 
  the premises at which the animals specified in the VFD are located; 
  the date of VFD issuance; 
  the expiration date of the VFD; 
8  Contains Nonbinding Recommendations 
  the name of the VFD drug(s); 
  the species and production class of animals to be fed the VFD feed; 
  the approximate number of animals to be fed the VFD feed by the expiration date of the 
VFD; 
  the indication for which the VFD is issued; 
  the level of VFD drug in the feed and duration of use; 
  the withdrawal time, special instructions, and cautionary statements necessary for use of 
the drug in conformance with the approval; 
  the number of reorders (refills) authorized, if permitted by the drug approval, conditional 
approval, or index listing; 
  the statement: Use of feed containing this veterinary feed directive (VFD) drug in a 
manner other than as directed on the labeling (extralabel use), is not permitted.; 
  an affirmation of intent for combination VFD drugs as described in  558.6(b)(6); and 
  the veterinarians electronic or written signature. 
 
Section 558.6(b)(4) permits the veterinarian to include on the VFD, at his or her discretion, the 
following additional information to identify more specifically the animals authorized to be fed 
the VFD feed: 
 
  A more specific description of the location of the animals (for example, by site, pen, 
barn, stall, tank, or other descriptor the veterinarian deems appropriate); 
  the approximate age range of the animals; 
  the approximate weight range of the animals; and 
  any other information the veterinarian deems appropriate to identify the animals specified 
in the VFD. 
 
2.  In what order should the information be included on the VFD? 
 
The order the information is presented is important to ensure that the VFD can be understood and 
the correct medicated VFD feed manufactured and distributed.  A common VFD format that a 
sponsor may use in order to meet the requirements of the regulations at  514.1(b)(9) and 
558.6(b) is shown in APPENDIX A.  FDA believes that using this common format will help 
clients, veterinarians, and distributors (including feed mills) quickly identify relevant information 
on the VFD, reduce the potential for typographical or other errors on the VFD, and reduce errors 
in using the VFD to manufacture feed or feed the VFD feed to animals. 
 
   
9  Contains Nonbinding Recommendations 
The common format in APPENDIX A contains the following features in the order listed below: 
 
1.  The contact information for the veterinarian and client.  Including this information first 
allows the veterinarian, distributor, and client to easily see who authorized the VFD and 
who will be using the VFD; 
 
2.  Information about the VFD drug and the required statement about extralabel use.  This 
information should be pre-populated by the sponsor on the VFD submitted to FDA as 
part of the new animal drug application.  In cases where a veterinarian uses a VFD that 
has not been pre-populated with the VFD drug-specific information, grouping this 
information together helps the veterinarian identify and copy the appropriate information 
from the label and completely fill in all of the relevant drug information; 
 
3.  Information about the animals for which the VFD is being authorized, including the 
required and discretionary information; 
 
4.  The affirmation of intent statements for VFD drugs that are approved, conditionally 
approved, or indexed to be used in combination with other animal drugs.  The statements  
also provide, if applicable, a checkbox for the veterinarian to affirm whether the use of 
the VFD drug is authorized: 1) in any approved, conditionally approved, or indexed 
combination containing the VFD drug as a component; 2) only in certain approved, 
conditionally approved, or indexed combinations containing the VFD drug as a 
component; or 3) in no approved, conditionally approved, or indexed combinations 
containing the VFD drug; 
 
5.  A section demarcated by compressed arrows that indicates the required drug withdrawal 
time.  Separating and demarcating this information from the other drug approval 
information makes it easy for the client to locate on the VFD; and 
 
6.  Information on the issuance and expiration date, as well as the veterinarians signature.  
Including this required element last will help the veterinarian ensure that they have 
completed all of the required information on the VFD before applying his or her signature 
to the VFD. 
 
APPENDIX B provides hypothetical examples of pre-populated VFDs using the features of this 
recommended common format, while APPENDIX C shows these same examples with all of the 
remaining relevant information subsequently filled out by the issuing veterinarian. 
 
3.  Do all three affirmation of intent statements need to be included for a VFD drug 
with no approved, conditionally approved, or indexed combination with other 
animal drug(s)? 
 
No.  If there is no approved, conditionally approved, or indexed combination of a VFD drug with 
other animal drug(s), only the first of the three affirmation of intent statements (the one specified 
in  558.6(b)(6)(i)) should be included to make it clear to the veterinarian that this VFD drug is 
not a component of any approved, conditionally approved, or index listed combination.  Such 
10  Contains Nonbinding Recommendations 
inclusion would also minimize the potential for the reader to think that lack of an affirmation of 
intent statement on the VFD is a mistake, and thus think that the VFD is incomplete.  When a 
VFD drug is a component of one or more approved, conditionally approved, or indexed 
combinations, all three affirmation of intent statements will need to be included, with 
checkboxes for the veterinarians to select their choice. 
 
4.  How does the recommended common format apply to an electronic VFD? 
 
Any VFD, whether paper or electronic, is required to include the information specified by 
regulation.  VFDs that are issued electronically may also follow this recommended common 
format. 
 
5.  The examples in the appendices do not include space for additional information a 
sponsor may want to include, such as a logo.  Can this information be included on 
the VFD? 
 
The examples provided in the appendices only include the required and discretionary information 
that is specified in the regulation.  You may use these templates as the starting point to develop a 
VFD that may contain additional information (e.g., logo, sequential VFD number).  However, 
keep in mind that additional information on the VFD can create confusion and make it more 
difficult to locate required information.  We recommend that additional information on a VFD be 
included in a place and manner that does not interfere with the information listed in  558.6(b). 
   
11  Contains Nonbinding Recommendations 
APPENDIX A:  BLANK VFD IN THE RECOMMENDED COMMON FORMAT 
 
   
12  Contains Nonbinding Recommendations 
APPENDIX B:  EXAMPLES OF VFDS IN THE RECOMMENDED COMMON 
FORMAT PRE-POPULATED BY THE SPONSOR FOR SUBMISSION TO CVM 
 
EXAMPLE 1:  A PRE-POPULATED VFD FOR A VFD DRUG THAT IS NOT 
APPROVED, CONDITIONALLY APPROVED, OR INDEXED FOR USE WITH 
OTHER ANIMAL DRUG(S) 
 
   
13  Contains Nonbinding Recommendations 
EXAMPLE 2:  A PRE-POPULATED VFD FOR A VFD DRUG THAT IS APPROVED, 
CONDITIONALLY APPROVED, OR INDEXED FOR USE WITH OTHER ANIMAL 
DRUG(S) 
 
14  Contains Nonbinding Recommendations 
APPENDIX C:  EXAMPLES OF PRE-POPULATED VFDS IN THE RECOMMENDED 
COMMON FORMAT THAT HAVE SUBSEQUENTLY BEEN COMPLETED BY THE 
ISSUING VETERINARIAN 
 
EXAMPLE 1:  A VFD DRUG THAT IS NOT APPROVED, CONDITIONALLY 
APPROVED, OR INDEXED FOR USE WITH OTHER ANIMAL DRUG(S) 
 
   
15  Contains Nonbinding Recommendations 
EXAMPLE 2: A VFD DRUG THAT IS APPROVED, CONDITIONALLY 
APPROVED, OR INDEXED FOR USE WITH OTHER ANIMAL DRUG(S) 
 
16